Review articleRecent advances in lipid-engineered multifunctional nanophytomedicines for cancer targeting
Graphical Abstract
Introduction
Hippocrates explain cancer as finger like projections which mind the crab shape [1,2]. Cancer is characterized by abnormal growth of cell with potential to invade other areas or distant part of body [[3], [4], [5]]. Different terms are used for explaining the cancers and malignant cells, with all depend on its origin whether it is sarcoma (like fat, bones, muscles, cartilages, and blood vessels), carcinoma (like skin or any internal tissue), leukemia (like bone marrow) or lymphoma (like immune system). As per WHO cancer report of 2018, it is second leading cause of death globally, which accounts for 9.6 million deaths [6,7]. Cancer cells have six prominent features: (i) self-sufficient signals; (ii) no sensitivity to anti-growth signals; (iii) apoptosis invasion; (iv) limited repetition in potential; (v) sustaining of angiogenesis; (vi) metastasis of tissue and its invasion [8]. Most common cancer includes lung, colorectal, prostate, liver, stomach and head-neck carcinomas. Symptoms and signs of cancer specifically depend on its size, type, location, extent to the tissues and organs. There are more than 100 types of cancers which exist till date. In humans, general signs and symptoms due to presence of cancer cells are incomprehensible events of pain, night sweats, fever, weight loss, unusual bowel movements, prominent events of cough, lumps [9,10].
Almost 30% of deaths arising due to cancer can be thwarted by slight modification or avoidance of risk factors. Various approaches employed for cancer treatment are hormone-based therapy, surgical interventions, chemotherapy, photodynamic therapy, immunotherapy, radiation therapy and genetic therapy [[11], [12], [13]]. Treatment choice depends on the stage and type of tumour and organ affected. For example, in case of non metastatic cancer, major goal is to eradicate tumour from regional lymph nodes and prevention of metastasis stage. Eradication of cancer can be achieved by surgical removal of cancer site and near by lymph nodes along with systemic administration of anti cancer moieties (preoperative or postoperative). In case of metastatic cancer, major goal is prolongation of life and decrease of morbidity. Presently, metastatic cancer remains incurable and systemic therapy is done to prolong the prognosis of disease. As per the WHO guidelines in which new treatment options were adopted with an initiative for cancer treatment especially in low- and middle-income nations [14,15]. Treatment of cancer is highly herculean task due to various unwanted events like aggression in proliferation of tumour and its spreading to multiple organs, therapeutic resistance, heterogenous in metastasis, barriers in drug permeation. Most common approach practiced in case of cancer therapy is chemotherapy but it imparts acute as well as chronic side effects to patients and thus overall hinders the quality of life [16]. Recent cancer treatment patterns have been changed with targeting to oncogenes and immune oncology-based cancerous ailments [17]. However, still there are miles of way existing for overcoming the challenges pertaining to cancer therapy. Sequence-based analysis for pre-screening of molecules in clinical research is advantageous but it restricts the clinical application owing to large volume of genomic data [18]. Also, precision-based oncology treatment is limited due to the heterogeneity as well as resistance acquired by cancer cells, while immune check-point inhibitors does not aid in success to cancer treatment due to lack of suitable validation process for markers.
Section snippets
Biopharmaceutical challenges for phytomedicines-based drug therapy
From ancient times, phytomedicines are used as the crucial source for drugs. Till date almost 50% of drugs are obtained from natural sources [19,20]. Most of the patients develop their interest towards the phytomedicine because of their low cost, better efficacy and very limited side-effects [21]. However, phytomedicines also reported to have compromised in vivo activity owing to more than one reasons like poor water solubility, lack of appropriate molecular sizing and compromised systemic
Lipid-based nanostructured drug delivery systems
Advancement in the field of science have discovered many novels and fulfilled the demand of healthcare facilities to great extent. Drug designing have paved the way for discovery of new anti-cancer molecules, but limited in clinical setup due to their compromised biopharmaceutical properties [30]. Till date micro or nano based phytoconstituents are not available in market. Most of the newly identified and isolated phytoconstituents suffers from poor solubility and bioavailability. Nano-based
Key challenges and critical considerationsin the design and development of phytomedicine-based lipidic nanotherapeutic systems
As per the literature reports, most of the phytomedicines derived from secondary metabolites exhibit limited bioavailability. Recent COVID-19 crisis has diverged the pharmaceutical industry interest towards the designing and development of herbal-based drug delivery systems as new treatment strategies [78,79]. Past studies like development of nanoparticles for Cuscuta chinensis, a Chinese traditional herbal medicine with pharmacological activity of rejuvenating the liver and kidney with
Surface engineering strategies for nanolipidic systems
Surface modification of nanocarriers is possible by coating of surface with mucoadhesive surfactants, polymers, stabilizers, ligands, etc. for impart various characteristics like mucoadhesion, stability, protein adsorption, zeta potential distribution and site-specific targeting of the nano-engineered particles. Surface modification also plays an important role in the cellular uptake of nanocarriers. Fig. 2 provides the overview of the strategies used for surface modification of the
Effective tumour targeting by phytomedicines-loaded lipidic nanoparticles and mechanistic insights
Amphiphilic nature of lipidic carriers enables the assemblage of single or combination of bilayer concentric structures which are well dispersed in water. Lipidic carriers provide an excellent alternative for various biopharmaceutical issues like insolubility, shortened half-life, toxicity and many more. Vesicular systems provide excellent entrapment for water insoluble drugs and enhance the solubility [96]. Furthermore, vesicular systems tend to delay the metabolism of drugs and protectthem
Clinical trials, regulatory status and commercial landscape
Luteolin (a flavonoid 3′,4′,5,7-tetrahydroxyflavone) nanoformulation is under Phase I trial for lip and oral cavity cancer. Initial in vitro studies were done on squamous cell carcinoma cell lines (TSCC, OSCC, HNSCC) which reveal promising results by targeting Caspase 3 gene expression and induces apoptosis [112,113]. Polyglutamate (a biodegradable polymer) conjugated with paclitaxel to form paclitaxel-poliglumex complex demonstrated more survival rate in females in comparison to males. This
Nanolipid bubbles (NLB)
NLBs are stabilized nano-sized lipid bubbles with outer covering of lipid and internal void structure. Recently, such carriers have attracted wider attraction in drug delivery imaging using the ultrasound guided targeting approach. NLBs have advantage like ease of penetration in tumour region with high drug loading capacity and drug stability. Till date, NLBs are explored for molecular imaging as well as drug and gene delivery applications. For instance, application in prostate cancer imaging
Future prospects and conclusions
Nanophytomedicines have proven to be highly effective inaugmenting the biological performance and reducingthe side-effects of conventional anticancer therapy. There is a general notion for nano-based therapeutic system is high cost over the conventional drug carriers. However, nano-based therapeutics has benefits of reducing the dose and maximizing efficacy. Various factors contributing the success of nanophytomedicines include regulatory approval process across the globe, geographical barriers
Declaration of Competing Interest
The authors declare no conflict of interest among themselves.
Acknowledgment
Authors, MH and RS acknowledge Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, under the aegis of Government of India, for financial support. The NIPER-R communication number for this article is NIPER-R/Communication/254. Also, the financial support provided by The Academy of Medical Sciences (UK) and Dept. of Biotechnology, Ministry of Science & Technology (India) in the form Newton International Fellowship (NIFR8\1038) to SB is gratefully acknowledged.
References (131)
- et al.
cancer treatment-induced accelerated aging in cancer survivors: biology and assessment
Cancers (Basel).
(2021) - et al.
Phytomedicine
- et al.
Saraf, recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives
J. Control. Release
(2016) - et al.
Lipid/polymer-based nanocomplexes in nucleic acid delivery as cancer vaccines
Drug Discov. Today
(2021) - et al.
Liposomal delivery systems for herbal extracts
J. Drug Deliv. Sci. Technol.
(2021) - et al.
Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment
Adv. Drug Deliv. Rev.
(2020) - et al.
Synergistic effect of PEGylated resveratrol on delivery of anticancer drugs
Int. J. Pharm.
(2016) - et al.
Influence of curcumin-loaded cationic liposome on anticancer activity for cervical cancer therapy
Colloids Surf. B: Biointerfaces
(2014) - et al.
Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma
Nanomed. Nanotechnol. Biol. Med.
(2012) - et al.
Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: an efficient carrier for cancer multi-drug delivery
Mater. Sci. Eng. C
(2015)
Nanoemulsion: promising nanocarrier system for delivery of herbal bioactives
J. Drug Deliv. Sci. Technol.
Formulation of saponin stabilized nanoemulsion by ultrasonic method and its role to protect the degradation of quercitin from UV light
Ultrason. Sonochem.
Lipid based nanoemulsifying resveratrol for improved physicochemical characteristics, in vitro cytotoxicity and in vivo antiangiogenic efficacy
Colloids Surf. B: Biointerfaces
Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells
Nanomed. Nanotechnol. Biol. Med.
Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies
Int. J. Pharm.
Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice
Eur. J. Pharm. Sci.
Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy
Adv. Drug Deliv. Rev.
Quality of herbal medicines: challenges and solutions
Comp. Ther. Med.
Lessons from hippocrates: time to change the cancer paradigm
Int. J. Chronic Dis.
[Hippocrates’ viewpoint on cancer]., Zhonghua Yi Shi Za Zhi
History of Cancer
A brief history of cancer: age-old milestones underlying our current knowledge database
Int. J. Cancer
Emergence of Nanophytomedicine in Health Care Setting, in: Nanophytomedicine
WHO | Cancer Factsheet, WHO
Introduction to pharmaceutical product development
WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All
Cancer
The biology of cancer
Med. (United Kingdom).
Symptoms in advanced cancer patients in a Greek Hospital: a descriptive study
Asian Pac. J. Cancer Prev.
Cancer symptom cluster management
Semin. Oncol. Nurs.
Epigenomics in cancer management
Cancer Manag. Res.
Cancer classification at the crossroads
Cancers (Basel).
Complementary therapies for symptom management in cancer patients
Indian J. Palliat. Care
Tumor microenvironment: recent advances in various cancer treatments
Eur. Rev. Med. Pharmacol. Sci.
Polycaprolactone based nano-carrier for co-administration of moxifloxacin and rutin and its In-vitro evaluation for sepsis
J. Drug Deliv. Sci. Technol.
Therapeutic potential of nanoemulsions as feasible wagons for targeting Alzheimer’s disease
Drug Discov. Today
Traditional medicine, modern science and the upgrading of the local pharmaceutical industry: endogenous development of the phytomedicine innovation system in Korea
Innov. Dev.
Trends and challenges in phytomedicine: research in the new millennium
Natural products chemistry and phytomedicine research in the new millennium: new developments and challenges
Arkivoc.
The application of phytomedicine in modern drug development
Internet J. Herb. Plant Med.
Challenges and future prospects of herbal medicine
Int. Res. Med. Heal. Sci.
Herbal medicine: clinical perspective & regulatory status
Comb. Chem. High Throughput Screen.
An overview of methods of extraction, isolation and characterization of natural medicinal plant products in improved traditional medicine research
Asian J. Res. Med. Pharm. Sci.
Introduction of nanotechnology in herbal drugs and nutraceutical: a review
J. Nanomed. Biotherapeutic Discov.
Nanotechnology-based drug delivery systems and herbal medicines: a review
Int. J. Nanomedicine
Application of nanotechnology to the extraction of herbal components for medicinal uses
Curr. Nanomater.
Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: systematic development, characterization and pharmacokinetic evaluation
Colloids Surf. B: Biointerfaces
Preparation, physicochemical characterization, and cell viability evaluation of long-circulating and ph-sensitive liposomes containing ursolic acid
Biomed. Res. Int.
Formulation and in vitro evaluation of berberine containing liposome optimized by 32 full factorial designs
J. Appl. Pharm. Sci.
Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer
Drug Deliv.
Cited by (18)
Fisetin nanoparticles based on cells cycle and apoptosis intervention for the treatment of lymphoma and leukemia
2024, International Journal of PharmaceuticsSupramolecular self-assembled peptide-engineered nanofibers: A propitious proposition for cancer therapy
2024, International Journal of Biological MacromoleculesChitosan nanoparticles as promising tool for berberine delivery: Formulation, characterization and in vivo evaluation
2023, Journal of Drug Delivery Science and TechnologyStimulus-responsive hybrid nanoparticles based on multiple lipids for the co-delivery of doxorubicin and Sphk2-siRNA and breast cancer therapy
2023, Food and Chemical ToxicologyCitation Excerpt :Nevertheless, the nanocarrier co-administration of DOX and siRNA, which can be simultaneously delivered to the same tumor cells, remains a major challenge because of its diverse properties (Khan et al., 2012; Li et al., 2018). Among the different nanocarriers, micelles and liposomes are extensively utilized for drug delivery owing to their prominent biocompatibility (Cengiz et al., 2015; Cullis and Hope, 2017; Handa et al., 2021). Herein, we synthesize dioleoyl ethanolamine (DE), a cationic phospholipid that can self-assemble with DOX to form a micelle and achieve the adsorption of siRNA molecules.
Construction of WS<inf>2</inf>/Au-lipid drug delivery system for multiple combined therapy of tumor
2022, Journal of Drug Delivery Science and TechnologyCitation Excerpt :The similar structure of liposomes and biological cell membranes makes it high biocompatibility and targeting profile to cancer cells, thereby improving the delivery efficiency of drugs and reducing the toxic and side effects. In addition, liposomes have a large surface area for loading a variety of anti-cancer drugs, making them quite advantageous as drug carriers [26–29]. After the drug-loaded liposomes are recognized and phagocytosed by macrophages, the drug can continue to be released to achieve long-term circulation [30].